Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms

References

• Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971;50:357–420.
   PubMed Web of Science ®Google Scholar
• Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997;11:233–242.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Idiopathic myelofibrosis. Am J Hematol 1990;34:291–300.
   PubMed Web of Science ®Google Scholar
• Tefferi A. The chronic myeloproliferative disorders. Semin Hematol 1999;36(Suppl. 2):3–8.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia N Engl J Med 2000;342:1255–1265.
   PubMed Web of Science ®Google Scholar
• Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41(Suppl. 3):1–5.
   PubMed Web of Science ®Google Scholar
• Fruchtman SM. Treatment paradigms in the management of chronic myeloproliferative disorders. Semin Hematol 2004;41(Suppl. 3):18–22.
   PubMed Web of Science ®Google Scholar
• Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275–290.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Barosi G, Cervantes F, . Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 2006;19:495–517.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683–692.
   PubMed Web of Science ®Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:421–445.
   PubMed Web of Science ®Google Scholar
• Gregory PD, Wagner K, Hortz W. Histone acetylation and chromatine remodeling. Exp Cell Res 2001;265:195–202.
   PubMed Web of Science ®Google Scholar
• Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81–120.
   PubMed Web of Science ®Google Scholar
• Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262:75–83.
   PubMed Web of Science ®Google Scholar
• Thiagalingam S, Cheng KH, Lee HJ, . Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003;983:84–100.
   PubMed Web of Science ®Google Scholar
• de Ruijter AJM, van Gennip AH, Caron HN, . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737–749.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459–5467.
   PubMed Web of Science ®Google Scholar
• Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004;73:417–435.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kwon HJ, Lee YM, . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437–443.
   PubMed Web of Science ®Google Scholar
• Schafer S, Jung M. Chromatin modifications as targets for new anticancer drugs. Arch Pharm (Weinheim) 2005;338:347–357.
   PubMed Web of Science ®Google Scholar
• Bi G, Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 2006;3:285–290.
   PubMed Web of Science ®Google Scholar
• Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595–606.
   PubMed Web of Science ®Google Scholar
• Martinez-Balbas MA, Bauer UM, Nielsen SJ, . Regulation of E2F1 activity by acetylation. EMBO J 2000;19:662–671.
   PubMed Web of Science ®Google Scholar
• Patel JH, Du Y, Ard PG, . The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004;24:10826–10834.
   PubMedGoogle Scholar
• Chen L, Fischle W, Verdin E, . Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001;293: 1653–1657.
   PubMed Web of Science ®Google Scholar
• Jeong JW, Bae MK, Ahn MY, . Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111:709–720.
   PubMed Web of Science ®Google Scholar
• Cohen HY, Lavu S, Bitterman KJ, . Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004;13:627–638.
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, . HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601–607.
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, . Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269–273.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li N, Caron C, . HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22: 1168–1179.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38–51.
   PubMed Web of Science ®Google Scholar
• Wang JC, Chen C, Dumlao T, . Enhanced histone deacetytase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008;49: 2321–2327.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, . A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150: 446–455.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, McMullin M; COSMYD Working Group and Nordic Myeloproliferative Study Group. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. EudraCT No. 2007-005306-49. Clinical trials identifier: NCT00866762.
   Google Scholar
• Irizarry RA, Hobbs B, Collin F, . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249–264.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article 3.
   Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289–300.
   Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37–50.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Oda Y, Eguchi T, . Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18: 769–774.
   PubMed Web of Science ®Google Scholar
• Osada H, Tatematsu Y, Saito H, . Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004;112:26–32.
   PubMed Web of Science ®Google Scholar
• Ishihama K, Yamakawa M, Semba S, . Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol 2007;60: 1205–1210.
   PubMed Web of Science ®Google Scholar
• Zhu P, Martin E, Mengwasser J, . Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455–463.
   PubMed Web of Science ®Google Scholar
• Marquard L, Poulsen CB, Gjerdum LM, . Histone deacetylase 1,2,6 and acetylated histone H4 in B-and T-cell lymphomas. Histopathology 2009;54:688–698.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Heaney MI, Schwartz I, . Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxyamic acid in patients with advanced haematological malignancies. J Clin Oncol 2006;24:166–173.
   PubMed Web of Science ®Google Scholar
• Huang BH, Laban M, Leung CH, . Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395–404.
   PubMed Web of Science ®Google Scholar
• Hrzenjak A, Moinfar F, Kremser ML, . Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther 2006;5:2203–2210.
   Google Scholar
• Weichert W, Roske A, Gekeler V, . Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604–610.
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Gekeler V, . Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139–148.
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Niesporek S, . Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14;1669–1677.
   PubMed Web of Science ®Google Scholar
• Krusche CA, Wulfing P, Kersting C, . Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005;90:15–23.
   PubMed Web of Science ®Google Scholar
• Marquard L, Gjerdrum LM, Christensen IJ, . Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267–277.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T, . HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962–6968.
   PubMed Web of Science ®Google Scholar
• Saji S, Kawakami M, Hayashi S, . Significance of HDAC6 regulation via estrogen signalling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24: 4531–4539.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, . Histone deacetylases in acute leukemia show a distinct pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751–1759.
   PubMed Web of Science ®Google Scholar
• Kato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 2004;279:41966–41974.
   PubMed Web of Science ®Google Scholar
• Bakin RE, Jung MO. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. J Biol Chem 2004;279:51218–51225.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, . Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumour activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102: 8567–8572.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Rao R, Fernandez P, . Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008;112: 2896–2905.
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2008;10:32–42.
   Web of Science ®Google Scholar
• Matsuyama A, Shimazu T, Sumida Y, . In vivo destabilization of dynamic microtubules by HDAC6 mediated deacetylation. EMBO J 2002;21:6820–6831.
   PubMed Web of Science ®Google Scholar
• Boyalt C, Zhang Y, Fritah S, . HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007;21:2172–2181.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kwon S, Yamaguchi T, . Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008;28:1688–1701.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T, . HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962–6968.
   PubMed Web of Science ®Google Scholar
• Lee YS, Lim KH, Guo X, . The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumourigenesis. Cancer Res 2008;68:7561–7569.
   PubMed Web of Science ®Google Scholar
• Zhou X, Marks PA, Rifkind RA, . Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA 2001;98: 10572–10577.
   PubMed Web of Science ®Google Scholar
• Petrie K, Guidez F, Howell L, . The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 2003;278: 16059–16072.
   PubMed Web of Science ®Google Scholar
• Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19:286–293.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Samuelsson J, . Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95:1216–1220.
   PubMed Web of Science ®Google Scholar
• Villagra A, Cheng F, Wang HW, . The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009;10:92–100.
   PubMed Web of Science ®Google Scholar
• Simonsson M, Heldin CH, Ericsson J, . The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 2005;280:21797–21803.
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, . Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269–273.
   PubMed Web of Science ®Google Scholar
• Han S, Lu J, Zhang Y, . HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. Immunol Lett 2007;108: 143–150.
   PubMed Web of Science ®Google Scholar
• Li B, Greene MI. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007;6:1432–1436.
   PubMed Web of Science ®Google Scholar
• Maltepe E, Krampitz GW, Okazaki KM, . Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta. Development 2005;132:3393–3403.
   PubMed Web of Science ®Google Scholar